CAR-T followed by antibody treatment for lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or refractory large B-cell lymphoma that has not responded to at least one prior standard treatment including an anthracycline and an anti-CD20 medicine
- You have no expected standard treatment left that would improve survival, based on your care team
- You can have study scanning that shows measurable lymphoma (a spot big enough to measure) on PET/CT, CT, or MRI within the required time windows around CAR-T
- You are at least 30 days past your CAR-T infusion when you enroll, and you can likely live at least 12 more weeks
- You do blood tests as needed and are able/willing to use reliable birth control during the study as required
- You can follow the study rules, including possibly staying in the hospital for required periods
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
This trial tests a special cell therapy called CAR-T that targets CD19 on lymphoma cells. It is for people with aggressive large B-cell lymphoma that has not responded to standard treatments or has come back after treatment.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.